• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    A unique and stable pharmaceutical preparation containing berberine, in slow formulation, with a statin and ubiquinol for the treatment of cardiovascular disease and its associated risk factors. The combination of berberine, in a slow release formulation to ensure its bioassimilation, coated with a statin and ubiquinol matrix in a unique presentation with medication quality will be a treatment of high efficiency and cheaper than the current ones. The combination of different complementary mechanisms of action, will allow to reduce the dose of statin, which will result in fewer side effects, also reduced by the supplement in ubiquinol (coenzyme Q10), so it would be a healthier formulation. The administration will be oral, so you will avoid the punctures that are always very unpopular among patients. Finally, the presence of all the components in a single drug will further promote adherence to treatment. (Machine-translation by Google Translate, not legally binding)
    公开号:ES2645028A1
    申请号:ES201731206
    申请日:2017-10-13
    公开日:2017-12-01
    发明作者:Maria D. GÓMEZ GARRE；Luca Severino VOLONTÉ
    申请人:Maria D. GÓMEZ GARRE；Luca Severino VOLONTÉ；
    IPC主号:
    专利说明:

    image 1
    image2
    image3
    image4
    image5
    image6
    权利要求:
    Claims (1)
    [1]
    image 1
    类似技术:
    公开号 | 公开日 | 专利标题
    PH12015502134A1|2016-01-25|Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration
    EA201690102A1|2016-06-30|PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYLFUMATE FOR INTRODUCTION TO LOW DAILY DOSE
    CY1115652T1|2017-01-25|DOSAGE FORM THAT CONTAINS TWO ACTIVE MEDICINAL MIXING INGREDIENTS IN DIFFERENT NATURAL FORMS
    BR112015004244A2|2017-07-04|orally administered medical composition
    EA201401028A1|2015-04-30|PHARMACEUTICAL COMPOSITION, CONTAINING EMAGOGLIFLOZIN AND MEDICINES FOR OBESITY
    JP2015523407A5|2016-09-23|
    AR084816A1|2013-06-26|METHODS AND MEDICINES FOR THE TREATMENT OF ALZHEIMER'S DISEASE
    JP2014507475A5|2015-04-23|
    MX2017013636A|2018-03-08|Tamper-resistant fixed dose combination providing fast release of two drugs from different particles.
    UY31790A|2009-12-14|USE OF DRONEDARONA TO PREPARE A MEDICINAL PRODUCT FOR THE TREATMENT OF PATIENTS WITH ARRITMIA AND THAT HAVE AN INCREASE OF THE CREATININE LEVEL DUE TO THE ADMINISTRATION OF DRONEDARONA
    MX2017005163A|2018-01-18|Onapristone extended-release compositions and methods.
    ES2645028A1|2017-12-01|A unique and stable pharmaceutical preparation containing berberine, in a slow-release formulation, a statin and ubiquinol for the treatment of cardiovascular disease and the associated risk factors |
    MX2017013633A|2018-03-08|Tamper-resistant fixed dose combination providing fast release of two drugs from particles.
    Sankar et al.2010|Design and development of Prochlorperazine Maleate sustained release tablets: Influence of hydrophilic polymers on the release rate and in vitro evaluation
    JP2006519209A5|2007-03-01|
    PH12016500120A1|2016-04-25|Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
    RU2014146562A|2016-06-10|ALPHA-LIPOIC ACID AND RACNOCIOLE COMPOSITION FOR THE TREATMENT OF NEUROPATHIES
    JP2019529554A5|2020-10-22|
    MX2018011293A|2019-02-13|Prolonged release pharmaceutical composition comprising cysteamine or salt thereof.
    JP2016193903A5|2017-01-05|
    MX2017013643A|2018-03-08|Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a matrix.
    WO2011126327A3|2012-02-02|Pharmaceutical composition with controlled-release properties comprising mosapride or levodropropizine, and preparing method thereof
    PH12019501607A1|2020-03-09|Tapentadol nasal composition
    Salman2016|Sorafenib/yttrium-90
    Kim et al.2021|Novel formulations and technologies can improve the delivery of levodopa
    同族专利:
    公开号 | 公开日
    WO2019073103A1|2019-04-18|
    ES2645028B2|2018-06-04|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    WO2001052822A1|2000-01-20|2001-07-26|Chopra Raj K|Reduced form of coenzyme q in high bioavailability stable dosage forms and related applications|
    WO2007090289A1|2006-02-09|2007-08-16|National Research Council Of Canada|Combinations of botanical extracts for promoting cardiovascular health|
    WO2014128639A1|2013-02-21|2014-08-28|Rondi Andrea|Composition for the treatment of metabolic disorders|
    US20170135995A1|2015-11-13|2017-05-18|Shenzhen Hightide Biopharmaceutical, Ltd.|Pharmaceutical compositions of berberine with epa and dha, and methods thereof|
    CN1759834B|2004-09-17|2010-06-23|中国医学科学院医药生物技术研究所|Application of berberine or associated with Simvastatin in preparing product for preventing or curing disease or symptom related to blood fat|
    法律状态:
    2018-06-04| FG2A| Definitive protection|Ref document number: 2645028 Country of ref document: ES Kind code of ref document: B2 Effective date: 20180604 |
    2018-10-23| PC2A| Transfer of patent|Owner name: FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSP Effective date: 20181017 |
    优先权:
    申请号 | 申请日 | 专利标题
    ES201731206A|ES2645028B2|2017-10-13|2017-10-13|Single and stable pharmaceutical preparation containing berberine, in slow-release formulation, a statin and ubiquinol for the treatment of cardiovascular disease and associated risk factors|ES201731206A| ES2645028B2|2017-10-13|2017-10-13|Single and stable pharmaceutical preparation containing berberine, in slow-release formulation, a statin and ubiquinol for the treatment of cardiovascular disease and associated risk factors|
    PCT/ES2018/070666| WO2019073103A1|2017-10-13|2018-10-15|Pharmaceutical composition for the treatment of cardiovascular diseases|
    [返回顶部]